Avillion LLP, a pharmaceutical co-development company, has appointed Ramani Varanasi as its chief business officer. Registered in London and funded by the venture capital groups Abingworth and Clarus Ventures, Avillion invests in late-stage clinical development projects. Ms Varanasi has worked for more than 18 years in the biotechnology and pharmaceutical industries in licensing, merger and acquisition transactions and in business development. Her employers have included Merck & Co, Millennium (Takeda), Momenta Pharmaceuticals, Archemix and RXi Pharmaceuticals. She holds a BSc and an MSc in microbiology/immunology and biochemistry respectively from McGill University in Canada and an MBA from Northeastern University in the US.
Avillion announced the appointment on 28 May 2013.
Copyright 2013 Evernow Publishing Ltd